Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07763171
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaGruppo Oncologico del Nord-OvestNot Yet RecruitingPhase 3
NCT07763171Not Yet Recruiting
Phase 3
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-neg...Gruppo Oncologico del Nor...
NCT07763548
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Minimize Propofol Injection PainErasme University HospitalNot Yet RecruitingPhase 4
NCT07763548Not Yet Recruiting
Phase 4
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Mini...Erasme University Hospita...
NCT07764133
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerUniversity of Tennessee Graduate School of MedicineRecruiting
NCT07764133Recruiting
—
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation a...University of Tennessee G...
NCT07762430
Food Noise Survey Development and Validation in Hindi and English-Speaking AdultsDiabetes Foundation, IndiaNot Yet Recruiting
NCT07762430Not Yet Recruiting
—
Food Noise Survey Development and Validation in Hindi and English-Speaking Adult...Diabetes Foundation, Indi...
NCT07763353
Effects of Slow-paced Breathing on Heart Rate Variability in Patients With Heart FailureChung Shan Medical UniversityNot Yet RecruitingNot Applicable
NCT07763353Not Yet Recruiting
Not Applicable
Effects of Slow-paced Breathing on Heart Rate Variability in Patients With Heart...Chung Shan Medical Univer...
NCT07763431
Home-Use Dual-Light Antibacterial Photodynamic Therapy for Peri-Implant Mucositis in Full-Arch Implant ProsthesesUniversity of Medicine and Pharmacy at Ho Chi Minh CityNot Yet RecruitingNot Applicable
NCT07763431Not Yet Recruiting
Not Applicable
Home-Use Dual-Light Antibacterial Photodynamic Therapy for Peri-Implant Mucositi...University of Medicine an...
NCT07763522
Validation of a Methodology Using Isometric Dynamometer for Ankle STrength Assessment to Quantify LDH-induced ParesisHelsinki University Central HospitalEnrolling By InvitationNot Applicable
NCT07763522Enrolling By Invitation
Not Applicable
Validation of a Methodology Using Isometric Dynamometer for Ankle STrength Asses...Helsinki University Centr...
NCT07763964
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763964Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07762833
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisGalderma R&DNot Yet RecruitingPhase 3
NCT07762833Not Yet Recruiting
Phase 3
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Sub...Galderma R&D
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07763158
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent Pain in Patients With Severe Knee OsteoarthritisKing Abdullah International Medical Research CenterRecruitingNot Applicable
NCT07763158Recruiting
Not Applicable
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent...King Abdullah Internation...
NCT07762313
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Humacyte, Inc.Not Yet RecruitingPhase 3
NCT07762313Not Yet Recruiting
Phase 3
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular...Humacyte, Inc.
NCT07762053
Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor TonometerEyeCBetter CorporationNot Yet RecruitingNot Applicable
NCT07762053Not Yet Recruiting
Not Applicable
Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomon...EyeCBetter Corporation
NCT07762872
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDChifeng Municipal HospitalRecruiting
NCT07762872Recruiting
—
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in...Chifeng Municipal Hospita...
NCT07761962
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversible PulpitisKing Abdullah University HospitalActive Not RecruitingNot Applicable
NCT07761962Active Not Recruiting
Not Applicable
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversib...King Abdullah University...
NCT07764016
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial DiseaseCardionovum GmbHNot Yet RecruitingNot Applicable
NCT07764016Not Yet Recruiting
Not Applicable
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scor...Cardionovum GmbH
NCT07763379
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERYSohag UniversityRecruiting
NCT07763379Recruiting
—
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKA...Sohag University
Result Breakdown
Not yet recruiting10 (50%)
Recruiting4 (20%)
Completed2 (10%)
Active, not recruiting2 (10%)
Enrolling by invitation1 (5%)
Unknown1 (5%)
not_applicable9 (45%)
Not Specified6 (30%)
Phase 33 (15%)
Phase 41 (5%)
Phase 11 (5%)